Anti-Senataxin, Polyclonal [OY11]
Invented by Dr Stephen West from Francis Crick Institute
Invented at Cancer Research UK London Research Institute: Clare Hall Laboratories
- Datasheet
- References (2)
- Inventor Info
Info
Catalogue Number | 151842 |
Applications | IP WB |
Antigen/Gene or Protein Targets | Senataxin |
Reactivity | Human |
Relevance | Defects in Senataxin are the cause of neurodegenerative diseases AOA-2 and ALS4. Senataxin play vital roles in DNA repair and transcription termination. The staining pattern of the antibody is located in the nucleus and chromatin. |
Host | Rabbit |
Immunogen | A mixture of four peptides corresponding to the following amino acid ranges of human Senataxin: aa8-30, aa884-895, aa1173-1192, aa2654-2677 |
Concentration | 1mg/mL |
Formulation | 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl. |
Molecular Weight (kDa) | 303 |
Notes | Stored in 0.1% sodium azide |
Positive Control | Whole-cell or Chromatin extracts of HeLa or HEK293 cells |
Research Area | Epigenetics & Nuclear Signalling, Neurobiology |
References: 2 entries
Yüce et al. 2013. Mol Cell Biol. 33(2):406-17. PMID: 23149945.
Senataxin, defective in the neurodegenerative disorder ataxia with oculomotor apraxia 2, lies at the interface of transcription and the DNA damage response.
Europe PMC ID: 23149945
Add a reference
References: 2 entries
Yüce et al. 2013. Mol Cell Biol. 33(2):406-17. PMID: 23149945.
Senataxin, defective in the neurodegenerative disorder ataxia with oculomotor apraxia 2, lies at the interface of transcription and the DNA damage response.
Add a reference